Thrombose und COVID-19

The prevalence of venous thromboembolism (VTE) events in Coronavirus diesease 2019 (COVID-19) patients is high, especially among those with severe disease. Patients with severe COVID-19 and VTE have significantly greater mortality compared with patients without VTE. The manifestation of a severe Severe acute respiratory syndrome coronavirus-2 (SARS-CoV‑2) infection is the systemic proinflammatory and procoagulant phenotype, associated with vascular thrombosis not only in veins, but also in arteries, capillaries and blood vessel inflammation. An increased D‑dimer level can be used as an indicator for VTE in patients with COVID-19. Medical societies have issued guidelines and recommend applying thromboprophylaxis, preferably with low molecular weight heparin (LMWH) in all patients during the hospital stay. Further evidence from ongoing randomized controlled trials (RCTs) of optimal anticoagulant and antithrombotic regimes is expected in the near future.